Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France
NCT ID: NCT05204342
Last Updated: 2022-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
22500 participants
OBSERVATIONAL
2012-01-01
2021-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
NCT01391351
Study of Predictive Factors of Chemoresistance in Ovarian Cancer
NCT02878122
Role of Surgery in Advanced Ovarian Cancer
NCT03980028
Systematic Lymphadenectomy During Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer
NCT06385912
French Observatory of Rare Malignant Tumors of the Ovary
NCT01304043
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* +/-
* Carcinose péritonéale C786
* Tumueur maligne secondaire de la plèvre C782,
* Tumueur maligne secondaire des ganglions C770 à C779,
* Tumueur maligne secondaire du foie C787,
* Tumueur maligne secondaire du péritoine C786
Exclusion Criteria
* Carcinose péritonéale C786
* Tumueur maligne secondaire de la plèvre C782,
* Tumueur maligne secondaire des ganglions C770 à C779,
* Tumueur maligne secondaire du foie C787,
* Tumueur maligne secondaire du péritoine C786
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martha DURAES, Md
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uhmontpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL21_0742
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.